0000000001099310

AUTHOR

Silvia Menendez

showing 3 related works from this author

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

2020

AbstractPurpose:Despite the therapeutic success of existing HER2-targeted therapies, tumors invariably relapse. This study aimed at identifying new mechanisms responsible for HER2-targeted therapy resistance.Experimental Design:We have used a platform of HER2-targeted therapy–resistant cell lines and primary cultures of healthy and tumor-associated fibroblasts (TAF) to identify new potential targets related to tumor escape from anti-HER2 therapies.Results:We have shown that TAFs promote resistance to HER2-targeted therapies. TAFs produce and secrete high levels of FGF5, which induces FGFR2 activation in the surrounding breast cancer cells. FGFR2 transactivates HER2 via c-Src, leading to res…

0301 basic medicineCancer ResearchReceptor ErbB-2medicine.medical_treatmentMice NudeBreast NeoplasmsDrug resistanceTargeted therapy03 medical and health sciencesMice0302 clinical medicineBreast cancerCancer-Associated FibroblastsTrastuzumabCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmAnimalsHumansReceptor Fibroblast Growth Factor Type 2skin and connective tissue diseasesneoplasmsbusiness.industryLapatinibTrastuzumabmedicine.diseaseXenograft Model Antitumor AssaysSurvival Rate030104 developmental biologyOncologyTumor EscapeApoptosisDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchFemaleSignal transductionNeoplasm Recurrence Localbusinessmedicine.drugSignal Transduction
researchProduct

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival

2019

Abstract Purpose: We investigated the value of tumor-infiltrating NK (TI-NK) cells and HLA class I tumor expression as biomarkers of response to neoadjuvant anti-HER2 antibody–based treatment in breast cancer. Experimental Design: TI-NK cells and HLA-I were determined by IHC in pretreatment tumor biopsies from two cohorts of patients with HER2-positive breast cancer [discovery cohort (n = 42) and validation cohort (n = 71)]. Tumor-infiltrating lymphocytes (TIL) were scored according to international guidelines. Biomarker association with pathologic complete response (pCR) and disease-free survival (DFS) was adjusted for prognostic factors. Gene set variation analysis was used for determinin…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryHuman leukocyte antigenmedicine.diseaseGene expression profiling03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerImmune systemOncology030220 oncology & carcinogenesisInternal medicineCohortmedicinebiology.proteinBiomarker (medicine)ImmunohistochemistryAntibodybusinessClinical Cancer Research
researchProduct

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.

2021

[Purpose]: To characterize expression of neuregulin-1 (NRG1), an HER3 ligand, in HER2-positive breast cancer and its relation with the efficacy of trastuzumab with or without pertuzumab.

Cancer ResearchStromal cellReceptor ErbB-2medicine.medical_treatmentNeuregulin-1Drug Evaluation PreclinicalBreast NeoplasmsAntibodies Monoclonal HumanizedBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabAntineoplastic Combined Chemotherapy Protocolsmental disordersmedicineTumor Cells CulturedHumansNeuregulin 1skin and connective tissue diseasesneoplasmsNeoadjuvant therapyRetrospective Studiesbiologybusiness.industryFibroblastsTrastuzumabmedicine.diseasebody regionsTreatment OutcomeOncologyCancer cellbiology.proteinCancer researchImmunohistochemistryFemalePertuzumabbusinessmedicine.drug
researchProduct